📊 PRPH Key Takeaways
Is ProPhase Labs, Inc. (PRPH) a Good Investment?
ProPhase Labs faces critical financial distress with revenue collapsed 80.6% YoY to just $3.6M while operating losses reached $12.3M, indicating fundamental business failure. With only $405K cash, a 0.14x current ratio indicating severe liquidity crisis, and negative $7.1M operating cash flow, the company has limited runway before potential insolvency.
Why Buy ProPhase Labs, Inc. Stock? PRPH Key Strengths
- Gross margin of 31.9% suggests product has inherent value when sold
- Moderate leverage with debt-to-equity of 0.43x provides some financial flexibility
- Zero capital expenditures indicate aggressive cost-cutting measures in place
PRPH Stock Risks: ProPhase Labs, Inc. Investment Risks
- Critical liquidity crisis: Current ratio of 0.14x leaves only 14 cents of current assets per dollar of obligations
- Catastrophic revenue decline of 80.6% YoY signals core business model failure or total loss of market position
- Negative operating cash flow of $7.1M with only $405K cash on hand creates imminent insolvency risk within weeks
- Net losses deteriorating 218% YoY with negative interest coverage of -23.9x indicates inability to service debt from operations
- Destroyed shareholder value with ROE of -107.1% and ROA of -11.2%
Key Metrics to Watch
- Cash position depletion rate and months of runway remaining
- Revenue stabilization or continued contraction trajectory
- Debt covenant compliance and refinancing ability
- Operating loss reduction path and timeline to cash flow breakeven
ProPhase Labs, Inc. (PRPH) Financial Metrics & Key Ratios
💡 AI Analyst Insight
The current ratio below 1.0x warrants monitoring of short-term liquidity.
PRPH Profit Margin, ROE & Profitability Analysis
PRPH vs Healthcare Sector: How ProPhase Labs, Inc. Compares
How ProPhase Labs, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is ProPhase Labs, Inc. Stock Overvalued? PRPH Valuation Analysis 2026
Based on fundamental analysis, ProPhase Labs, Inc. shows some fundamental concerns relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
ProPhase Labs, Inc. Balance Sheet: PRPH Debt, Cash & Liquidity
PRPH Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: ProPhase Labs, Inc.'s revenue has grown significantly by 141% over the 5-year period, indicating strong business expansion. The most recent EPS of $-0.98 indicates the company is currently unprofitable.
PRPH Revenue Growth, EPS Growth & YoY Performance
PRPH Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $883.0K | -$6.6M | $-0.16 |
| Q2 2025 | $1.2M | -$506.0K | $-0.01 |
| Q1 2025 | $1.4M | $4.0M | $0.11 |
| Q3 2024 | $3.1M | -$5.1M | $-0.30 |
| Q2 2024 | $2.5M | -$2.9M | $-0.17 |
| Q1 2024 | $3.6M | $550.0K | $0.03 |
| Q3 2023 | $8.4M | $968.0K | $0.06 |
| Q2 2023 | $13.2M | -$2.9M | $-0.17 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
ProPhase Labs, Inc. Dividends, Buybacks & Capital Allocation
PRPH SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for ProPhase Labs, Inc. (CIK: 0000868278)
📋 Recent SEC Filings
❓ Frequently Asked Questions about PRPH
What is the AI rating for PRPH?
ProPhase Labs, Inc. (PRPH) has an AI rating of STRONG SELL with 97% confidence, based on fundamental analysis of SEC EDGAR filings.
What are PRPH's key strengths?
Claude: Gross margin of 31.9% suggests product has inherent value when sold. Moderate leverage with debt-to-equity of 0.43x provides some financial flexibility.
What are the risks of investing in PRPH?
Claude: Critical liquidity crisis: Current ratio of 0.14x leaves only 14 cents of current assets per dollar of obligations. Catastrophic revenue decline of 80.6% YoY signals core business model failure or total loss of market position.
What is PRPH's revenue and growth?
ProPhase Labs, Inc. reported revenue of $3.6M.
Does PRPH pay dividends?
ProPhase Labs, Inc. does not currently pay dividends.
Where can I find PRPH SEC filings?
Official SEC filings for ProPhase Labs, Inc. (CIK: 0000868278) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is PRPH's EPS?
ProPhase Labs, Inc. has a diluted EPS of $-0.19.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is PRPH a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, ProPhase Labs, Inc. has a STRONG SELL rating with 97% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is PRPH stock overvalued or undervalued?
Valuation metrics for PRPH: ROE of -107.1% (sector avg: 15%), net margin of -206.3% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy PRPH stock in 2026?
Our dual AI analysis gives ProPhase Labs, Inc. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is PRPH's free cash flow?
ProPhase Labs, Inc.'s operating cash flow is $-7.1M, with capital expenditures of $0.0. FCF margin is -199.8%.
How does PRPH compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -206.3% (avg: 12%), ROE -107.1% (avg: 15%), current ratio 0.14 (avg: 2).